Abstract
Mepolizumab, an anti-interleukin-5 monoclonal antibody has been shown to increase remission duration in patients with eosinophilic granulomatosis with polyangiitis (EGPA). We investigated impact of baseline treatment, disease duration, and refractory status on mepolizumab efficacy using Phase III MIRRA study data.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
